This paper examines issues impacting the global generics sector and the role of Indian generics companies. The USA, which has been the primary regulated market focus for Indian companies, and the EU, are covered. Key success factors for generics companies are described. Various approaches by Indian companies to selling in the regulated markets are discussed, including partnership and direct selling models, and Indian competitive advantages and weaknesses compared to global and regional generics companies described.
Get full access to this article
View all access options for this article.
References
1.
Presentation by LewisGraham, Vice President, IMS Health, UK at the 8th Annual IGPA Conference, Malta, 21st June, 2005.
2.
NDCHealth Pharmaceutical Audit Suite (PHAST) Prescription Monthly.
‘Drug master file issues at the Office of Generic Drugs’, presentation by Paul Schwartz, Deputy Director, Division of Chemistry I, Office of Generic Drugs, CDER, US Food and Drug Administration at the GPhA 2005 API Conference/DCAT Week, New York, 15th March, 2005.
6.
UBS Investment Research Q Series: ‘India Pharmaceuticals, can India become the global pharmaceutical factory?’ Research report dated 23rd June, 2005 by UBS India Analyst Prashant Vaishampayan and Associate Analyst Krupa Thacker.
7.
Market share data from IMS. Analysis by UBS India Analyst Prashant Vaishampayan.
8.
‘Ranbaxy Pharmaceuticals Inc., USA, receives prestigious outstanding supplier award from Wal-Mart’, press release dated 21st June, 2005, www.ranbaxyusa.com.
9.
Comments from Ranbaxy CEO Brian Tempest, during his presentation at the ABN AMRO Global Generic Pharmaceutical Conference: The Emerging Role of Indian Pharma, Mumbai, 9th March, 2005.
